Tonix Pharmaceuticals (NASDAQ:TNXP) Posts Earnings Results, Misses Estimates By $3.54 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP) issued its earnings results on Tuesday. The company reported ($9.77) EPS for the quarter, missing analysts’ consensus estimates of ($6.23) by ($3.54), Zacks reports. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.58 million during the quarter, compared to analysts’ expectations of $3.20 million.

Tonix Pharmaceuticals Price Performance

TNXP opened at $16.47 on Thursday. The company has a fifty day simple moving average of $18.69 and a 200 day simple moving average of $19.75. The firm has a market cap of $30.78 million, a price-to-earnings ratio of 0.00 and a beta of 2.23. Tonix Pharmaceuticals has a twelve month low of $6.76 and a twelve month high of $1,184.00. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday, February 10th. They issued a “sell” rating on the stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.